

ADULT HAEMOGLOBINOPATHY ANNUAL REVIEW

PATIENT DETAILS (label)			Date of current	Annual Review *		
			Date of last Ann	ual Review *		
			Diagnosis *			
(* Denotes mandator	y questions)		8			
Did patient attend Ar	nual Review?		No O	Yes		
ABOUT THE PATIENT						
Height(cm)	Weight(kg)	Spleen Size(cm)	ВР	Oxygen Sa	aturation	
Urine dip						
Centre Changed in th	is review period *		No	Yes		
			0	0		
					Transferred to	
Patient Status *		Active	No longer Seen	Patient died	other center	
		0	0	0	0	
		Secondary Care	Specialist Haemo	oglobinopathy		
Your center is this pat	tient's *	Center (LHT)	Team (SHTC)			
		0	\circ			
	/A 0.5	- A - 11		٦		
Number of Emergenc	y (A&E or Urgent day cai	re) attendances				
		Ne	V			
Does the patient have an emergency care		No	Yes			
plan		O	O			
8:14b	abilidia dhia antana	ed No	V			
Did the patient have a child in this review period (To be answered by both male and female)		_	Yes		*	
(10 be allowered by b	Jui male and remale)	O	0			
Outcome of pregnanc	y (select one item)					
C Section	Preterm baby	/ <36 weks	Spontaneous Mis	carriage		
Live Birth	ND			Therapeutic termination		
Has the patient had ar	ny Red Cell Antibodies		No	Yes	Unknown	
			\bigcirc	\bigcirc		

"这条是是这种国际的	全国的发展的			特性有限的基本设计	30亿美国	PO ASSESSED	Ministra
COMPLICATIONS *				No	Yes		
				0			
Complication details				Date	Comme	ents	7
Acute Chest Syndrome	<u> </u>						_
Avascular Necrosis	0				4		
Bone Problem	ŏ				-		
Hepatitis B	00				1		
Chronic Hepatitis C	Ŏ				1		
Gallstones	Ŏ				1		
Headaches	Ö				1		
HIV	Positive	Negative	Unknown		J		
		0	0]		
Leg Ulcers) 50 5		1		
Multi Organ Failure	00000				1		
Osteomyelitis	0				1		
Parvovirus	Q						
Pneumococcal Infection	Ō]		
Priapism	Ö]		
	Echo-	2.1	Proven by Cardi		,		
Pulmonary Hypertension	cardiogram	Other	Proven by Cardia Catheter	iC			
Pulmonary rrypertension		\bigcirc	_		1		
Renal Failure	000000000	0	0		4		
Severe Septicemia	\sim			ļ	1	ı	
Sickle Retinopathy	\mathcal{C}				1	1	
Splenic Sequestration	\mathcal{C}				4	1	
Stroke	\sim				4	V	
TIA	\sim				4		
Other Bacteraemia					4		
Visual Symptoms	\sim				1		
					1		
Oher	0]	1	
	· · · · · · · · · · · · · · · · · · ·	dkoskstveksky					•
TRANSFUSIONS	明然是必须的特殊更多		AND THE PARTY OF T	HEROTEN HOLDER	新科技型的 2015年		和學學學
Regular Transfusions in this r	"ovious period *		A1-a				
Regular fransiusions in ans.	eview period		No	Yes			
- C-1 D-1-11-			0	0			
Tranfusion Details Transfusion at St Georges?			Kr.,	V.			
If ansitusion at 5t Georges.			No	Yes			
			0	0			
Туре			Auto Exchange	Manual E	Tychange	Tanlin	
1765			Auto Exchange	ivianuai E	.xcnange	Top Up	
			O	\circ		0	
Frequency of Transfusions (in	n weeks)						
,	To make &	,	(value between 1-				
			(value z	-61			_
Average units per Transfusion	Average units per Transfusion episode						
-			(value between 0-	_ /-15)			
			Peripheral		Long Term		
Usual Venous Acccess			Access		Indwelling Line		
			0	^	0		
				-	C		
Year Transfusion Started							
Tour Transcon.				_			
Have regular transfusion stop	oped in this period?	>	No	Yes			
500 Marie 1990	P		0	0			J
			\circ	\circ			

Adhoc Transfusions in this review period (Transfusions not part of a transfusion regime)		No O	Yes		
How many Episodes of Adhoc Tra	insfusions				
VACCINATIONS				T	
Vaccinations in this review period		Date of Vaccination	Expiry of Vaccination	Comment	s
Childhood schedule	0		- Comment		
Haemophilus	0				
Hepatitis B booster	0				
Influenza Meningitis + Hib (menitorix)	000000000				
Meningitis Group C conjugate	Ö				
Pneumovax	Ŏ				
Prevenar	0				1
Other	0				
In the second second					
INVESTIGATIONS		No	Yes		
		0	0		
Investigations in this review perlod Audiometry	_	Date	Result	Coments	
Bone Profile					
Brain MRI/MRA	000000000				
DEXA	0				
Echocardiogram	O				
Ferritin	0				
Fructosamine FSH/LH	0				
Glucose Tolerance Test	Ö				
Liver Function	Ŏ				
Mean Haemoglobin Untransfused	Q				
Microalbuminuria	0				
Oestrogen(for females) Opthalmology review	0				
PTH	Ö				
Sleep Studies	Ŏ				
Steady State Untransfused	0				
Testosterone (for males) Urine/Protein Creatinine ratio	00000000000			-	
Thyroid	0				
Viral Serology Hep Bs Ab	ŏ				
Нер С					
HCV Ab HIV	O		-		
Vitamin D	0000				
Other	Õ				

SPECIALIST IMAGING	MADI Compliant manufacture		_	MDILimor	
Ferriscan result	MRI Cardiac result T2* (ms)			MRI Liver result T2* (ms)	
result	12 (1113)			12 (1113)	
Forrisan			7	MDIII	
Ferriscan date	MRI Cardiac T2* date			MRI Liver T2* date	

Serious adverse event reported				No O	Yes
Number of serious adverse events					-
Serious Adverse Event					Date of event
		· ·			
Medications in this review period	Continued	Dose	Start date	End date	Comments
Ace Inhibitors	0				
Biphosphonates 🔘					
Folic Acid	0				
Hydroxycarbamide 🔘	0				
Penicillin V O	0				
Vitamin D			-		
Other	0				
Jane Chalation in this project and	.	[c	Te		
Iron Chelation in this review period Desferoxamine	Continued	Start date	End date	Cor	mments
Deferiprone O	0000				
Deferasirox O	Ŏ				
Desferoxamine +	0				
Deferiprone					
Operations in this review period		Operation date		Comments	
Adenotonsilectomy	0				-
Hip replacement	0				
Laparascopic Othorpaedic	000000				
Retinal Surgery	0				
Splenectomy	Ŏ				
Cholecystectomy					14
Other	0				
		· 中国的 (1000年末年100日本)			
Additional Comments					
- in the second					
Name	_				
Signature		Date			

Annual Review Pro forma

DISCUSSION CHECKLIST (tick all that apply and	document)
Acute care plan:	Emergency department:
Home pain plan:	
Chronic pain review: Opiate use	
Referral to pain management:	
Adherence to medications:	
Discussion of infection prevention and need for	or early treatment:
Review of visual symptoms:	
Referral to other specialist services:	
Fertility/contraception. Pre-pregnancy counse	elling:
Priapism:	
Discussion of therapeutic options currently av patient eligible for a clinical trial?	ailable and new information including ongoing trials. Is the
Emotional and psychosocial well-being; is psyc	chology referral needed?
Holistic assessment – lifestyle, education, worl services.	c or welfare issues. Consideration of referral to community
Offer additional information: Include key conta	act details, NHR information, local patient support groups,
Offer patient satisfaction survey (optional)	
Any other comments:	
Referral for MDT (local or network) discussion	if needed.
Management Plan: (Insert acute pain plan actio	on points from consultation)
Date:	